Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is impli
'/>"/>

SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  CVS Health is thanking its 26,000 pharmacists ... changing the way health care is delivered to increase ... retail pharmacies, mail service pharmacies and specialty pharmacies nationwide.  ... name to CVS Health to reflect our broader health ... needed to shape the future of health," said ...
(Date:9/30/2014)... - Protecting the health and safety of Canadians is our government,s ... powers and tools at its disposal to help ensure that the ... To that end, Health Canada ... Canada of all drug products from three plants ... , Apotex Pharmachem India Pvt Ltd , Apotex Research ...
(Date:9/30/2014)... BEDFORD, Mass. , Sept. 30, 2014  Hologic, ... Stephen MacMillan , Hologic,s President and Chief Executive ... Bell Ceremony on October 1, the first day of ... will discuss the Company,s campaign focused on the important ... system approved by the FDA as clinically superior to ...
Breaking Medicine Technology:CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
... , Knights of Columbus partners with Medishare to provide physical therapy and prosthetic limbs ... WASHINGTON , Aug. 4 ... aid of every Haitian child who lost a limb in the January earthquake that ... Many thousands more were seriously injured, including hundreds of children who lost arms and ...
... OvaGene Oncology Inc., a biotechnology ... DNA-based diagnostics for gynecologic cancer, is pleased to announce ... the Industry Collaboration Team (ICT) program.  By becoming a ... to building a strong partnership with the GOG research ...
Cached Medicine Technology:New Program Makes Prosthetics Available to All Haitian Children Who Lost Limbs in Earthquake 2OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research 2OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research 3
(Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... and the District of Columbia now have a total of ... that has been infecting children since the summer, U.S. ... virus have died in recent weeks, but it,s not clear ... those deaths, officials said. Health officials are also trying ...
(Date:10/1/2014)... associated with Alzheimer,s disease; however, researchers are still looking ... agent of the onset and development of the disease. ... is not harmful when found in isolation but only ... form the so-called amyloid fibrils , "We are not ... multiple ones because each aggregate of peptide, which can ...
(Date:10/1/2014)... eye, the brain of a rat and a robot ... a QUT leading robotics researcher. , Dr Michael ... new study uses new computer algorithms to enable robots ... , "This is a very Frankenstein type of project," ... a thing together because we,re taking the eyes of ...
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3
... among the scientific community about whether women who are ... to shed some light on this issue, scientists from ... methods used to detect substances in breast milk, their ... in this month,s issue of the journal Analytical ...
... Andrew Lees, Professor of Neurology at University College London, is ... Memorial Medal awarded for the scientific contributions he has ... He will receive the medal following his delivery of ... Stuff," at Barts and The London Medical School on June ...
... stromal tumors (GISTs) are the most common mesenchymal ... location is less common. Nowadays, surgery is ... procedures can be performed to remove duodenal GIST. ... difficult reconstruction (like pancreaticoduodenectomy; PD). One of the ...
... increase the risk of severe asthma attacks among people with ... Medical School, Harvard Pilgrim Health Care Institute and Brigham and ... the American Thoracic Society,s journal Web site ahead of the ... Critical Care Medicine . "We found that the interaction ...
... Council for Graduate Medical Education (ACGME) task force ... presented a comprehensive set of draft standards that ... better match residents, levels of experience and emerging ... patient care in the nation,s teaching hospitals. ...
... Texas (CPRIT) has granted $3.7 million to Rice University ... The funds will help the BioScience Research Collaborative ... Bioengineering and Chemistry, in its mission to make the ... into cancer and other diseases. The work ...
Cached Medicine News:Health News:Breast milk transmits drugs and medicines to the baby 2Health News:Breast milk transmits drugs and medicines to the baby 3Health News:Lord Brain Memorial Lecture is launched in recognizing outstanding contribution to neuroscience 2Health News:Moldy homes a serious risk for severe asthma attacks in some 2Health News:ACGME task force proposes graduated duty hour and supervision standards 2Health News:ACGME task force proposes graduated duty hour and supervision standards 3Health News:ACGME task force proposes graduated duty hour and supervision standards 4Health News:ACGME task force proposes graduated duty hour and supervision standards 5Health News:Rice wins $3.7 million for cancer research 2
... PalmScan P2000 Pachymeter [i.e., PalmScan P2000] ... operated biometer, which incorporates A-mode pulsed-echo ... to accurately measure the corneal thickness ... eyes. PalmScan P2000 includes two software ...
The Cordis ANGIOGUARD® Capture Guidewire is the first embolic protection device shown in clinical testing to achieve a relative stroke reduction of 70% during carotid stenting procedures....
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: